The Food and Drug Administration is introducing sweeping reforms to stop misleading pharmaceutical advertisements.
As part of the initiative, the FDA sent thousands of letters warning pharmaceutical companies to remove misleading ads and issuing approximately 100 cease-and-desist letters to companies with deceptive ads.
The FDA is also taking steps to close the "adequate provision" loophole created in 1997, which they claim drug companies have used to conceal critical safety risks in broadcast and digital ads, fueling inappropriate drug use and eroding public trust.
FDA Commissioner Dr. Marty Makary noted drug companies spent 25% of their budget on advertising.
"Those billions of dollars would be better spent on lowering drug prices for everyday Americans," he said.
A 2024 review in the Journal of Pharmaceutical Health Services Research reveals that while 100% of pharmaceutical social media posts highlight drug benefits, only 33% mention potential harms.
The study found 88% of advertisements for top-selling drugs are posted by individuals and organizations that fail to adhere to the FDA fair balance guidelines.
The FDA also stopped sending warning letters to drug companies in recent years, sending only one for all of 2023 and 2024.
The agency said it will aggressively deploy its available enforcement tools and is already implementing AI and other tech-enabled tools to proactively surveil and review drug ads.
The U.S. is the only country besides New Zealand that allows direct advertising of drugs to consumers.
In 1997, the FDA established a loophole that enabled pharmaceutical companies to run direct-to-consumer (DTC) advertisements without fully disclosing information on side effects or patient harm.
This led to a massive increase in advertising prescription drugs. According to MediaRadar, drug companies spent $10.8 billion in 2024 on direct-to-consumer pharmaceutical advertising.
Sam Barron ✉
Sam Barron has almost two decades of experience covering a wide range of topics including politics, crime and business.
© 2025 Newsmax. All rights reserved.